Copyright (c) 2015 AJC
This work is licensed under a Creative Commons Attribution 4.0 International License.
Monotropically More Stable Novel Polymorph of Nitazoxanide with Improved Aqueous Solubility
Corresponding Author(s) : Ram Bhavani
Asian Journal of Chemistry,
Vol. 27 No. 12 (2015): Vol 27 Issue 12
Abstract
Nitazoxanide [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate] is a drug used for antiprotozoal treatment. This drug belongs to biopharmaceutics classification system (II) and presently available in two high oral dosage forms-tablet (500 mg) and oral suspension (100 mg per 5 mL when reconstituted). A monotropically more stable novel polymorphic form (Form II) of nitazoxanide with improved aqueous solubility has been identified and fully characterized by a variety of analytical techniques such as powder X-ray diffraction, differential scanning calorimeter, thermogravimetric analysis, Karl Fischer titration, infrared spectroscopy, solution state nuclear magnetic resonance, polarized microscopy and high performance liquid chromatography techniques. Aqueous solubility of Form II is increased by 2.76 folds. Form II is obtained from less toxic and environment friendly Class III organic solvent ethanol.
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
- L.K.V. Narayana, Y.N. Manohara and R.S. Appala, Indian Drugs, 43, 503 (2006).
- L.A.M. Fox and L.D. Saravolatz, Clin. Infect. Dis., 40, 1173 (2005); doi:10.1086/428839.
- J. Muller, M. Sterk, A. Hemphill and N. Muller, J. Antimicrob. Chemother., 60, 280 (2007); doi:10.1093/jac/dkm205.
- J.-F. Rossignol, New Derivatives of 2-Benzamido 5-Nitrothiazoles, US Patent, 3,950,351 (1976).
- H. Brittain, Physical Characterization of Pharmaceutical Solids, Marcel Dekker, New York (1995).
- S.R. Byrn, Solid-State Chemistry of Drugs, SSCI Inc., New York, edn 2 (1999).
- J. Haleblian and W. McCrone, J. Pharm. Sci., 58, 911 (1969); doi:10.1002/jps.2600580802.
- S.R. Vippagunta, H.G. Brittain and D.J.W. Grant, Adv. Drug Deliv. Rev., 48, 3 (2001); doi:10.1016/S0169-409X(01)00097-7.
- K.T. Savjani, A.K. Gajjar and J.K. Savjani, ISRN Pharmaceut., Article ID 195727 (2012); doi:10.5402/2012/195727.
- E.H. Kerns, J. Pharm. Sci., 90, 1838 (2001); doi:10.1002/jps.1134.
- A. Burger and R. Ramberger, Mikrochim. Acta, 72, 259 (1979); doi:10.1007/BF01197379.
References
L.K.V. Narayana, Y.N. Manohara and R.S. Appala, Indian Drugs, 43, 503 (2006).
L.A.M. Fox and L.D. Saravolatz, Clin. Infect. Dis., 40, 1173 (2005); doi:10.1086/428839.
J. Muller, M. Sterk, A. Hemphill and N. Muller, J. Antimicrob. Chemother., 60, 280 (2007); doi:10.1093/jac/dkm205.
J.-F. Rossignol, New Derivatives of 2-Benzamido 5-Nitrothiazoles, US Patent, 3,950,351 (1976).
H. Brittain, Physical Characterization of Pharmaceutical Solids, Marcel Dekker, New York (1995).
S.R. Byrn, Solid-State Chemistry of Drugs, SSCI Inc., New York, edn 2 (1999).
J. Haleblian and W. McCrone, J. Pharm. Sci., 58, 911 (1969); doi:10.1002/jps.2600580802.
S.R. Vippagunta, H.G. Brittain and D.J.W. Grant, Adv. Drug Deliv. Rev., 48, 3 (2001); doi:10.1016/S0169-409X(01)00097-7.
K.T. Savjani, A.K. Gajjar and J.K. Savjani, ISRN Pharmaceut., Article ID 195727 (2012); doi:10.5402/2012/195727.
E.H. Kerns, J. Pharm. Sci., 90, 1838 (2001); doi:10.1002/jps.1134.
A. Burger and R. Ramberger, Mikrochim. Acta, 72, 259 (1979); doi:10.1007/BF01197379.